• 1. Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510000, P.R.China;
  • 2. School of Public Health, Sun Yet-Sen University, Guangzhou 510000, P.R.China;
  • 3. Eclincloud (Shenzhen) Technology Co., Ltd, Shenzhen 518038, P.R.China;
  • 4. South China Research Center for Acupuncture and Moxibustion, Clinical Research and Data Center, Guangzhou University of Chinese Medicine, Guangzhou 510000, P.R.China;
  • 5. Department of Gerontology Department of Clinical Research, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, P.R.China;
  • 6. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510000, P.R.China;
YANG Zhongqi, Email: yang_zhongqi@163.com; LING Li, Email: lingli@mail.sysu.edu.cn; LU Liming, Email: lulimingleon@gzucm.edu.cn
Export PDF Favorites Scan Get Citation

Under the background of global COVID-19 pandemic, the electronic informed consent (eConsent) utilizes technology to provide a new method and idea for clinical trials. It has the advantages of convenience and efficiency, which greatly improves the efficiency of clinical trials. At present, this concept has not been put forward in China while it has been clarified clearly at abroad, and some countries have launched a variety of trials and formulated various regulations to further standardize the eConsent. Based on the current situation of eConsent in China, analyze the design and implementation of eConsent, summarize relevant domestic and foreign laws and regulations, and propose opportunities and challenges for electronic informed consent as well as the relevant preparations for the implementation of this technology in China.